omomyc peptide an Omomyc peptide could be used as a pharmacological therapeutic approach - Omomycmechanism of action Recombinant Omomyc is a Cell-penetrating Peptide Omomyc Peptide: A Novel Therapeutic Approach Targeting MYC in Cancer

Myc targeting by omo 103 in solid tumors a phase 1 trial pubmed The omomyc peptide, also referred to as omoMYC, represents a groundbreaking therapeutic strategy in the fight against cancer. This innovative peptide is designed to directly inhibit the MYC oncoprotein, a protein frequently dysregulated in various malignanciesPeptomyc SL now aims tofurther develop the Omomyc peptide- and improved variants - into clinically viable therapeutics for the treatment of cancer patients.. As the first MYC inhibitor in clinical trials, Omomyc has demonstrated significant promise in preclinical models and is now advancing through human studies.

Omomyc functions as a dominant-negative MYC peptide. It is essentially a truncated version of the MYC protein, specifically engineered to contain the Myc DNA-binding domain and a coiled-coil region.OmoMYC blunts promoter invasion by oncogenic MYC to ... This structure allows Omomyc to bind to the same DNA sequences as the oncogenic MYC protein, thereby blocking its ability to promote uncontrolled cell growth and proliferation. Research has shown that OmoMYC causes the largest decreases in promoter occupancy and significant changes in the expression of genes that are typically invaded by oncogenic MYC levelsTumor penetrating peptides inhibiting MYC as a potent .... This direct interference with MYC's transcriptional activity is crucial for halting tumor progression.

One of the key advantages of Omomyc is its inherent ability to penetrate cells2025年8月21日—The outcomes of this study suggest that the inhibition of c-Myc exerted byOmomyc peptidereduces significantly cell growth and migration.. The purified Omomyc mini-protein itself exhibits excellent cell penetrating properties, spontaneously entering cancer cells without the need for external delivery vehiclesPeptomyc's Omomyc-based therapy, OMO-103, has .... This intrinsic cell-penetrating activity is a significant advancement, as it allows the therapeutic peptide to reach its target within the cell efficiently.作者：E Wang·2019·被引用次数：94—We foundFPPa-OmoMYCto be a potent inducer of apoptosis (with IC50 from 1-2 µM) in TNBC cells with negligible effects in non-tumorigenic cells. Indeed, Omomyc is the first cell-penetrating peptide targeting MYC for cancer therapyThe invention relates to a combination of an immuno-oncology agent withOmomyc, a functionally equivalent variant thereof, a conjugate comprisingOmomyc.. Studies have indicated that Recombinant Omomyc is a Cell-penetrating Peptide, facilitating its therapeutic action. This characteristic is vital for its effectiveness, as demonstrated by its ability to induce rapid tumor regression in mouse models with minimal observed toxicity.

The development and refinement of Omomyc have led to its advancement into clinical trials. The Omomyc-based therapy, OMO-103, has garnered substantial attention. OMO-103 is a first-in-class Pan-MYC-Inhibitor currently being evaluated in patients with advanced solid tumors. A Phase 1 trial investigating the MYC targeting by OMO-103 in solid tumors has provided valuable insights into its safety and preliminary efficacy. Furthermore, Peptomyc's Omomyc-based therapy, OMO-103, has obtained approval for first-in-human phase I/II trial to assess its efficacy and safety. This progression signifies a major milestone in translating Omomyc peptide research from the laboratory to patient care.作者：F Giuntini·2025·被引用次数：3—Here, we show thatOmomyc, the only direct MYC inhibitorthat has completed a phase 1 trial, shuts down DDR genes in triple-negative breast ...

Beyond its direct application, Omomyc is also being explored in combination therapiesAnti-Omomyc [21-1-3] | Monoclonal Antibodies. Research is investigating the potential of combining an immuno-oncology agent with Omomyc, or a functionally equivalent variant thereof. The EV20/Omomyc conjugate, for instance, links an anti-HER3 antibody to Omomyc, aiming for a dual targeting approachOmomyc is the first cell-penetrating peptide targeting MYC for cancer therapywhich is now being evaluated in clinical trials in cancer patients.. Such strategies aim to enhance therapeutic outcomes by leveraging multiple anti-cancer mechanisms. The potential for Omomyc peptide to be used as a pharmacological therapeutic approach, either by direct delivery or in combination, is a testament to its versatility.

The mechanism of action of Omomyc is multifaceted.Pharmacokinetic Analysis of Omomyc Shows Lasting ... It has been shown to reduce the ability of MYC to bind specific E-box sequences in the promoters of MYC target genes. This direct binding to E-box sequences is a critical aspect of its inhibitory function.Omomyc Reveals New Mechanisms To Inhibit the MYC ... Additionally, research suggests that Omomyc inhibits MYC and causes DNA damage, potentially by shutting down DNA Damage Response (DDR) genesOmomyc Reveals New Mechanisms To Inhibit the MYC .... This dual action—blocking MYC's transcriptional activity and inducing DNA damage—could contribute to its potent anti-cancer effects. The observation that omoMYC coacervates result in reduced proliferation and apoptosis induction further supports its cytotoxic potential against cancer cellsTechnology.

The journey of Omomyc from a laboratory tool to a potential clinical therapeutic has been remarkable. Initially designed and published in 1998 as a laboratory tool to study MYC perturbation, Omomyc has evolved significantly over the past two decades作者：MJ Demma·2019·被引用次数：111—The MYC inhibitorOmomyccan reduce the ability of MYC to bind specific box sequences in promoters of MYC target genes by binding directly to E box sequences.. Companies like Peptomyc SL are dedicated to further develop the Omomyc peptide and improved variants into clinically viable therapeutics for the treatment of cancer patients5I4Z: Structure of apo OmoMYC. Their efforts are crucial in bringing this promising MYC inhibitor to those who can benefit from it. The ongoing research and clinical trials underscore the ongoing commitment to understanding and harnessing the power of the omomyc peptide to combat cancer.